Faiella, M.; Botti, G.; Dalpiaz, A.; Gnudi, L.; Goyenvalle, A.; Pavan, B.; Perrone, D.; Bovolenta, M.; Marchesi, E.
In Vitro Studies to Evaluate the Intestinal Permeation of an Ursodeoxycholic Acid-Conjugated Oligonucleotide for Duchenne Muscular Dystrophy Treatment. Pharmaceutics 2024, 16, 1023.
https://doi.org/10.3390/pharmaceutics16081023
AMA Style
Faiella M, Botti G, Dalpiaz A, Gnudi L, Goyenvalle A, Pavan B, Perrone D, Bovolenta M, Marchesi E.
In Vitro Studies to Evaluate the Intestinal Permeation of an Ursodeoxycholic Acid-Conjugated Oligonucleotide for Duchenne Muscular Dystrophy Treatment. Pharmaceutics. 2024; 16(8):1023.
https://doi.org/10.3390/pharmaceutics16081023
Chicago/Turabian Style
Faiella, Marika, Giada Botti, Alessandro Dalpiaz, Lorenzo Gnudi, Aurélie Goyenvalle, Barbara Pavan, Daniela Perrone, Matteo Bovolenta, and Elena Marchesi.
2024. "In Vitro Studies to Evaluate the Intestinal Permeation of an Ursodeoxycholic Acid-Conjugated Oligonucleotide for Duchenne Muscular Dystrophy Treatment" Pharmaceutics 16, no. 8: 1023.
https://doi.org/10.3390/pharmaceutics16081023
APA Style
Faiella, M., Botti, G., Dalpiaz, A., Gnudi, L., Goyenvalle, A., Pavan, B., Perrone, D., Bovolenta, M., & Marchesi, E.
(2024). In Vitro Studies to Evaluate the Intestinal Permeation of an Ursodeoxycholic Acid-Conjugated Oligonucleotide for Duchenne Muscular Dystrophy Treatment. Pharmaceutics, 16(8), 1023.
https://doi.org/10.3390/pharmaceutics16081023